Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma.
Takayesu JSK, Parvathaneni U, Laramore GE, Panjwani N, Sillings J, Futran ND, Humphreys IM, Jafari A, Abuzeid WM, Barber B, Marchiano E, Lee SM, Thompson JA, Hall E, Bhatia S, Rodriguez CP, Liao JJ. Takayesu JSK, et al. Among authors: thompson ja. Cancer Rep (Hoboken). 2025 Feb;8(2):e70111. doi: 10.1002/cnr2.70111. Cancer Rep (Hoboken). 2025. PMID: 39907094 Free PMC article.
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. Hamid O, et al. Among authors: thompson ja. J Immunother Cancer. 2022 Oct;10(10):e005471. doi: 10.1136/jitc-2022-005471. J Immunother Cancer. 2022. PMID: 36302562 Free PMC article. Clinical Trial.
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson JA. Leidner R, et al. Among authors: thompson ja. J Immunother Cancer. 2023 Oct;11(10):e007725. doi: 10.1136/jitc-2023-007725. J Immunother Cancer. 2023. PMID: 37907221 Free PMC article. Clinical Trial.
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
Gross EE, Li M, Yin M, Orcutt D, Hussey D, Trott E, Holt SK, Dwyer ER, Kramer J, Oliva K, Gore JL, Schade GR, Lin DW, Tykodi SS, Hall ET, Thompson JA, Parikh A, Yang Y, Collier KA, Miah A, Mori-Vogt S, Hinkley M, Mortazavi A, Monk P, Folefac E, Clinton SK, Psutka SP. Gross EE, et al. Among authors: thompson ja. Urol Oncol. 2023 Jan;41(1):51.e25-51.e31. doi: 10.1016/j.urolonc.2022.08.013. Epub 2022 Oct 26. Urol Oncol. 2023. PMID: 36441070 Free PMC article.
Immune Checkpoint Inhibitor-Induced Colitis.
S Thomas A, Lu Y, Campbell M, Thompson JA, Tan D, Faleck DM, Wang Y. S Thomas A, et al. Among authors: thompson ja. Gastroenterology. 2025 Jan;168(1):21-28. doi: 10.1053/j.gastro.2024.09.034. Epub 2024 Oct 9. Gastroenterology. 2025. PMID: 39389184 No abstract available.
1,138 results